Tscan therapeutics appoints leiden dworak, cpa, mba, as vice president, finance

Waltham, mass., april 11, 2022 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr) engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the appointment of leiden dworak, cpa, mba, as vice president, finance. mr. dworak brings to tscan over a decade of experience in financial infrastructure implementation and operations management in early/mid-stage biotech.
TCRX Ratings Summary
TCRX Quant Ranking